The Centre for Aging + Brain Health Innovation (CABHI) awarded access to its Mentorship, Capital and Continuation (MC2) program to Rehabtronics in January. The program helps companies unlock funding to accelerate business growth by providing access to leading investors, buyers, industry leaders and advisory from Silicon Valley.
Each year, the Centre for Aging and Brain Health Innovation (CABHI) awards runs its Mentorship, Capital and Continuation (MC2) program, designed to help healthtech companies whose solutions improve the lives of aging adults. Earlier this year, Rehabtronics was one of six companies to be awarded access to MC2, which unlocked access to leading investors, buyers, industry leaders and advisors from Silicon Valley. The company is already seeing results.
“Thanks to the advisors and resources from the MC2 Program, we achieved key commercialization milestones including financing, and have accelerated Prelivia’s path to market,” reports Dr. Rahul Samant, CEO of Rehabtronics.
An established company with a decade of success developing and delivering products that help people recover movement after central or peripheral nervous system injury or disease, Rehabtronics is currently seeking funding to commercialize a new product to help alleviate pressure injuries in people who are bedridden or chair bound.
More commonly known as bedsores, pressure injuries affect up to 2.5 million patients in North America each year and are considered one of the most expensive and deadly hospital-acquired injuries. Prelivia is the first technology designed to prevent damage by restoring blood circulation and tissue oxygenation.
Responsive Health Initiates Prelivia Pilot to Combat Pressure Injuries at Long-Term Care Home
Responsive Health Management Initiates Prelivia Pilot to Combat Pressure Injuries at Long-Term Care Home
Rehabtronics Receives $1.25 Million from Genome BC to Enable Free Quality Improvement Trials of Prelivia
Rehabtronics Receives $1.25 Million from Genome BC to Enable Free Quality Improvement Trials of Prelivia, a Medical Device Designed to Protect Against Deadly Pressure Damage
Rehabtronics Raises $1.6 Million in Oversubscribed Funding
The Clinical and Financial Burden of Pressure Injuries
FDA Clears Prelivia, a Medical Device that Protects Patients from Pressure Injuries at Hospitals and Care Homes
Prelivia Receives FDA Clearance
The U.S. Food and Drug Administration has provided 510 (k) Clearance for Prelivia, a neurostimulation device that promotes healthy blood circulation and maintains healthy tissue in people who are bedridden or chair bound. Annually, more than 2.5 million people in the United States suffer from pressure injuries, also known as bed sores, and up to 60,000 people die.